Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder

Name: Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder
SKU: 23572
Price: 30.00 USD
Availability: InStock

$30.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Category: VOL 50 No. 3 Articles 2020 Tags: alcohol use disorder, biotransformation, Bryun, cyp2d6, depressive spectrum disorders, duloxetine, Grishina, Koporov, Pankratenko, personalized medicine, Petukhov, pharmacogenetics, Ryzhikova, Skryabin, Sychev, Zastrozhin

Description

Description

Drug Disposition & Pharmacokinetics

Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder

By Zastrozhin, Petukhov, Pankratenko, Grishina, Ryzhikova, Skryabin, Koporov, Bryun, Sychev

Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder

Description

Drug Disposition & Pharmacokinetics

Vicki L. Ellingrod, PharmD, BCPP: 5-HT2A Receptor Promoter Polymorphism, -1438G/A and Negative Symptom Response to Olanzapine in Schizophrenia

Association of CYP2D6*4 Polymorphism with the Steady- State Concentration of Haloperidol in Patients with Alcohol-Induced Psychotic Disorders

A Pilot Study of the Pharmacodynamic Impact of SSRI Drug Selection and Beta-1 Receptor Genotype (ADRB1) on Cardiac Vital Signs in Depressed Patients: A Novel Pharmacogenetic Approach

Impact of Recent Methamphetamine Use on Vancomycin Clearance

Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder

Description

Drug Disposition & Pharmacokinetics

Related products

Vicki L. Ellingrod, PharmD, BCPP: 5-HT2A Receptor Promoter Polymorphism, -1438G/A and Negative Symptom Response to Olanzapine in Schizophrenia

Association of CYP2D6*4 Polymorphism with the Steady- State Concentration of Haloperidol in Patients with Alcohol-Induced Psychotic Disorders

A Pilot Study of the Pharmacodynamic Impact of SSRI Drug Selection and Beta-1 Receptor Genotype (ADRB1) on Cardiac Vital Signs in Depressed Patients: A Novel Pharmacogenetic Approach

Impact of Recent Methamphetamine Use on Vancomycin Clearance